Peking Union Medical College Hospital is conducting a phase 2 interventional trial to look at the impact hetrombopag, a type of thrombopoietin receptor agonist (TPO-RA), has on reducing sustaining a high platelet count post treatment. During the study, participants will receive this TPO-RA and then the dosage of hetrombopag (2.5mg/d~7.5mg/d) will be adjusted based on the patient's platelet count. After 24-weeks of using the TPO-RA treatment, patients with a platelet count greater than 50,000 after two consecutive clinic visits will then enter an eight-week treatment reduction period. All patients who discontinued hetrombopag and maintained a platelet count above 30,000 will then be entered into an efficacy and safety follow-up period to investigate whether this ‘treatment reducing strategy’ could lead to the development or achievement of immune tolerance, achieving sustained response off treatment (SROT) requiring no other ITP-specific medications, and no bleeding after TPO-RA discontinuation.
Eligibility is restricted to adult patients, over 18 years of age, with a confirmed diagnosis of primary ITP, and who can achieve a platelet count of at least 100,000 using hetrombopag.
China
Status: Actively Recruiting